ITOVEBI

• druginavolisib12 co-mentions · 3 sources
• tagApproval12 co-mentions · 3 sources
• companyGenentech Inc6 co-mentions · 3 sources
• tagSmall Molecule6 co-mentions · 3 sources

Trials studying ITOVEBI

• phase3A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapyactive not recruitingn=420
• phase3A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Canceractive not recruitingn=325
• phase3A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Studyrecruitingn=100
• phase1To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Canceractive not recruitingn=200
• phase2A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumorsactive not recruitingn=176
• phase1A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisibrecruitingn=32
• phase1A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutationactive not recruitingn=498
• phase2To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancerrecruitingn=80